File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children

TitleInherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children
Authors
KeywordsCOVID-19
multisystem inflammatory syndrome in children
SARS-CoV-2
type I interferon
Issue Date1-Apr-2023
PublisherElsevier
Citation
Journal of Allergy and Clinical Immunology, 2023, v. 151, n. 4, p. 832-840 How to Cite?
Abstract

Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID. (J Allergy Clin Immunol 2023;151:832-40.)


Persistent Identifierhttp://hdl.handle.net/10722/331406
ISSN
2023 Impact Factor: 11.4
2023 SCImago Journal Rankings: 3.701
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBucciol, Giorgia-
dc.contributor.authorMeyts, Isabelle-
dc.contributor.authorAbel, Laurent-
dc.contributor.authorAl-Muhsen, Salah-
dc.contributor.authorAiuti, Alessandro-
dc.contributor.authorAl-Mulla, Fahd-
dc.contributor.authorAndreakos, Evangelos-
dc.contributor.authorAntonio, Novelli-
dc.contributor.authorArias, Andrés A-
dc.contributor.authorTrouillet-Assant, Sophie-
dc.contributor.authorBelot, Alexandre-
dc.contributor.authorBiggs, Catherine M-
dc.contributor.authorBousfiha, Ahmed A-
dc.contributor.authorBolze, Alex-
dc.contributor.authorBorghesi, Alessandro-
dc.contributor.authorBrodin, Petter-
dc.contributor.authorChristodoulou, John-
dc.contributor.authorCobat, Aurélie-
dc.contributor.authorCondino-Neto, Antonio-
dc.contributor.authorConstantinescu, Stefan-
dc.contributor.authorDalgard, Clifton L-
dc.contributor.authorEspinosa-Padilla, Sara-
dc.contributor.authorFellay, Jacques-
dc.contributor.authorFlores, Carlos-
dc.contributor.authorFranco, José Luis-
dc.contributor.authorFroidure, Antoine-
dc.contributor.authorGorochov, Guy-
dc.contributor.authorHaerynck, Filomeen-
dc.contributor.authorHalwani, Rabih-
dc.contributor.authorHsieh, Elena WY-
dc.contributor.authorItan, Yuval-
dc.contributor.authorKisand, Kai-
dc.contributor.authorLau, Yu-Lung-
dc.contributor.authoret al-
dc.date.accessioned2023-09-21T06:55:25Z-
dc.date.available2023-09-21T06:55:25Z-
dc.date.issued2023-04-01-
dc.identifier.citationJournal of Allergy and Clinical Immunology, 2023, v. 151, n. 4, p. 832-840-
dc.identifier.issn0091-6749-
dc.identifier.urihttp://hdl.handle.net/10722/331406-
dc.description.abstract<p></p><p>Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID. (J Allergy Clin Immunol 2023;151:832-40.)<br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofJournal of Allergy and Clinical Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectmultisystem inflammatory syndrome in children-
dc.subjectSARS-CoV-2-
dc.subjecttype I interferon-
dc.titleInherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children-
dc.typeArticle-
dc.identifier.doi10.1016/j.jaci.2023.02.003-
dc.identifier.scopuseid_2-s2.0-85149863960-
dc.identifier.volume151-
dc.identifier.issue4-
dc.identifier.spage832-
dc.identifier.epage840-
dc.identifier.isiWOS:000982200500001-
dc.identifier.issnl0091-6749-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats